M.C. Berchier

633 total citations
26 papers, 479 citations indexed

About

M.C. Berchier is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, M.C. Berchier has authored 26 papers receiving a total of 479 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 6 papers in Epidemiology. Recurrent topics in M.C. Berchier's work include Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Research Studies (17 papers) and Lung Cancer Diagnosis and Treatment (8 papers). M.C. Berchier is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Research Studies (17 papers) and Lung Cancer Diagnosis and Treatment (8 papers). M.C. Berchier collaborates with scholars based in Belgium, France and Greece. M.C. Berchier's co-authors include G. Bureau, Jean‐Paul Sculier, O Van Cutsem, V. Giner, Jean Klášterský, Marianne Paesmans, P. Mommen, G Dabouis, J Thiriaux and J. Lecomte and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

M.C. Berchier

26 papers receiving 465 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M.C. Berchier Belgium	14	363	281	161	132	33	26	479
H Karnicka-Młodkowska Poland	9	391 1.1×	202 0.7×	225 1.4×	99 0.8×	13 0.4×	24	464
K. Hans Germany	10	463 1.3×	312 1.1×	220 1.4×	148 1.1×	18 0.5×	23	591
D. Skarlos Greece	9	282 0.8×	100 0.4×	181 1.1×	131 1.0×	16 0.5×	16	363
L. E. James United Kingdom	8	301 0.8×	189 0.7×	158 1.0×	127 1.0×	24 0.7×	10	436
Van Echo Da United States	9	290 0.8×	138 0.5×	177 1.1×	116 0.9×	46 1.4×	18	393
T. Berghmans Belgium	8	296 0.8×	289 1.0×	76 0.5×	89 0.7×	12 0.4×	16	413
Xanthi Tsiafaki Greece	11	598 1.6×	571 2.0×	137 0.9×	161 1.2×	41 1.2×	36	762
Isabel R. Preeshagul United States	11	191 0.5×	106 0.4×	76 0.5×	72 0.5×	16 0.5×	28	306
Kamal Haider Canada	11	345 1.0×	133 0.5×	117 0.7×	45 0.3×	31 0.9×	36	428
L. Bigay-Gamé France	10	126 0.3×	193 0.7×	43 0.3×	72 0.5×	17 0.5×	32	343

Countries citing papers authored by M.C. Berchier

Since Specialization

Citations

This map shows the geographic impact of M.C. Berchier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.C. Berchier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.C. Berchier more than expected).

Fields of papers citing papers by M.C. Berchier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.C. Berchier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.C. Berchier. The network helps show where M.C. Berchier may publish in the future.

Co-authorship network of co-authors of M.C. Berchier

This figure shows the co-authorship network connecting the top 25 collaborators of M.C. Berchier. A scholar is included among the top collaborators of M.C. Berchier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.C. Berchier. M.C. Berchier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sculier, Jean‐Paul, J.J. Lafitte, Anna Efremidis, et al.. (2008). A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer. Annals of Oncology. 19(10). 1691–1697. 21 indexed citations

Sculier, Jean‐Paul, J.J. Lafitte, Marianne Paesmans, et al.. (2007). Chemotherapy improves low performance status lung cancer patients. European Respiratory Journal. 30(6). 1186–1192. 20 indexed citations

Berchier, M.C., Thierry Berghmans, Benoît Colinet, et al.. (2007). European Lung Cancer Working Party Clinical Practice Guidelines. Small Cell Lung Cnacer: IV. Limited disease. 2(2). 74–82. 1 indexed citations

Berghmans, T., J.J. Lafitte, J. Lecomte, et al.. (2007). Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party. British Journal of Cancer. 96(11). 1644–1649. 10 indexed citations

Sculier, Jean‐Paul, J.J. Lafitte, J. Lecomte, et al.. (2007). A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer. Annals of Oncology. 18(6). 1037–1042. 18 indexed citations

Berghmans, T., J.J. Lafitte, Marianne Paesmans, et al.. (2005). A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. Lung Cancer. 50(1). 75–82. 22 indexed citations

Lothaire, Philippe, Thierry Berghmans, Jean‐Jacques Lafitte, et al.. (2003). Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I-IIIa non-small cell lung cancer conducted by the European Lung Cancer Working Party. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 22. 1 indexed citations

Jp, Sculier, M Paesmans, J. Lecomte, et al.. (2001). A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. British Journal of Cancer. 85(10). 1444–1451. 41 indexed citations

Sculier, Jean‐Paul, Marianne Paesmans, Jean‐Jacques Lafitte, et al.. (1999). Prognostic factors analysis for response to chemotherapy and survival in a prospective cohort of patients with unresectable locoregional non small cell lung cancer initially treated by induction chemotherapy. Clinical & Translational Oncology. 1(2). 92–100. 2 indexed citations

10.

Sculier, J.P., Marianne Paesmans, J Thiriaux, et al.. (1999). A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Journal of Cancer. 35(9). 1314–1319. 20 indexed citations

11.

Sculier, Jean‐Paul, Marianne Paesmans, J.J. Lafitte, et al.. (1999). A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. Annals of Oncology. 10(3). 295–304. 24 indexed citations

12.

Jp, Sculier, Marianne Paesmans, J Thiriaux, et al.. (1998). Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.. Journal of Clinical Oncology. 16(4). 1388–1396. 24 indexed citations

13.

Sculier, Jean‐Paul, Marianne Paesmans, Vincent Ninane, et al.. (1998). Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small cell lung cancer treated by induction chemotherapy. Lung Cancer. 22(3). 201–213. 11 indexed citations

14.

Paesmans, Marianne, J.P. Sculier, J Thiriaux, et al.. (1997). 161 Carboplatin prescribed in mg/m2 in patients with advanced non small cell lung cancer (NSCLC): Is there an impact of the reached area under the curve (AUC) on response, survival and hematological toxicity?. Lung Cancer. 18. 43–44. 4 indexed citations

15.

Sculier, Jean‐Paul, M Paesmans, G. Bureau, et al.. (1996). Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party.. Journal of Clinical Oncology. 14(8). 2337–2344. 54 indexed citations

16.

Sculier, Jean‐Paul, Marianne Paesmans, Michel Richez, et al.. (1996). Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer (NSCLC). Lung Cancer. 16(1). 21–33. 24 indexed citations

17.

Sculier, Jean‐Paul, M Paesmans, P Libert, et al.. (1994). Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer. European Journal of Cancer. 30(9). 1342–1347. 28 indexed citations

18.

Klášterský, Jean, J.P. Sculier, F. Ries, et al.. (1994). A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 11(5-6). 373–384. 5 indexed citations

19.

Sculier, Jean‐Paul, Marianne Paesmans, G. Bureau, et al.. (1993). Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party.. Journal of Clinical Oncology. 11(10). 1858–1865. 61 indexed citations

20.

Body, Jean‐Jacques, Marianne Paesmans, Sculier Jp, et al.. (1992). Monoclonal Immunoradiometric Assay and Polyclonal Radioimmunoassay Compared for Measuring Neuron-Specific Enolase in Patients with Lung Cancer. Clinical Chemistry. 38(5). 748–751. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact